Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in?

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 8, 2013, Pages 551-559

  Patel, Sheila K ^a   Velkoska, Elena ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme 2; Cardiovas cular disease; Coronary artery disease; Heart failure; Renin angiotensin system

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7]; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DX 600; EDETIC ACID; MESSENGER RNA; MLN 4760; UNCLASSIFIED DRUG;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIRCULATION; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; EMERGENCY SURGERY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; ENZYME SYNTHESIS; GERIATRIC PATIENT; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MICROALBUMINURIA; NONHUMAN; ORTHOPEDIC SURGERY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; X CHROMOSOME;

EID: 84880990079     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12069     Document Type: Review

References (61)

1. Mendis S, Puska P, Norrving B (eds). Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization, Geneva. 2011.
2. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23: 258-68.
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens. Suppl. 2005; 23: S9-17.
4. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000; 87: E1-9.
5. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000; 275: 33238-43.
6. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002; 277: 14838-43.
7. Santos RA, Simoes e Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl Acad. Sci. USA 2003; 100: 8258-63.
8. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1-7): An evolving story in cardiovascular regulation. Hypertension 2006; 47: 515-21.
9. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-9.
10. Towler P, Staker B, Prasad SG et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004; 279: 17996-8007.
11. Guy JL, Jackson RM, Acharya KR, Sturrock ED, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2 (ACE2): Comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003; 42: 13185-92.
12. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004; 203: 631-7.
13. Bernardi S, Zennaro C, Palmisano S et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J. Renin Angiotensin Aldosterone Syst. 2012; 13: 202-9.
14. Garg M, Angus PW, Burrell LM, Herath C, Gibson PR, Lubel JS. Review article: The pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment. Pharmacol. Ther. 2012; 35: 414-28.
15. Tikellis C, Johnston CI, Forbes JM et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr. Eye Res. 2004; 29: 419-27.
16. Tikellis C, Johnston CI, Forbes JM et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392-7.
17. Mizuiri S, Hemmi H, Arita M et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 2008; 51: 613-23.
18. Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008; 74: 1610-16.
19. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007; 292: R373-81.
20. Paizis G, Tikellis C, Cooper ME et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut 2005; 54: 1790-6.
21. Burrell LM, Risvanis J, Kubota E et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur. Heart J. 2005; 26: 369-75.
22. Ohtsuki M, Morimoto S, Izawa H et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int. J. Cardiol. 2010; 145: 333-4.
23. 2 receptors in rabbit atherosclerotic plaques. J. Histochem. Cytochem. 2006; 54: 147-50.
24. 4R are present in diseased human blood vessels. Eur. J. Histochem. 2008; 52: 39-44.
25. Sluimer JC, Gasc JM, Hamming I et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol. 2008; 215: 273-9.
26. Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: The first decade. Int. J. Hypertens. 2012; 2012: 307315.
27. Zhang H, Wada J, Hida K et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J. Biol. Chem. 2001; 276: 17132-9.
28. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ. Res. 2006; 98: 463-71.
29. Hashimoto T, Perlot T, Rehman A et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 2012; 487: 477-81.
30. Lambert DW, Yarski M, Warner FJ et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 2005; 280: 30113-19.
31. Lambert DW, Clarke NE, Hooper NM, Turner AJ. Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett. 2008; 582: 385-90.
32. Lew RA, Warner FJ, Hanchapola I et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp. Physiol. 2008; 93: 685-93.
33. Jia HP, Look DC, Tan P et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009; 297: L84-96.
34. Lai ZW, Hanchapola I, Steer DL, Smith AI. Angiotensin-converting enzyme 2 ectodomain shedding cleavage-site identification: Determinants and constraints. Biochemistry 2011; 50: 5182-94.
35. Iwata M, Silva Enciso JE, Greenberg BH. Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. Am. J. Physiol. Cell Physiol. 2009; 297: C1318-29.
36. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin angiotensin system blockade and angiotensin converting enzyme 2 in experimental myocardial infarction: Implications for future therapeutic directions. Clin. Sci. 2012; 123: 649-58.
37. Burchill L, Velkoska E, Dean RG et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp. Physiol. 2008; 93: 622-30.
38. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006; 48: 914-20.
39. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008; 52: 750-4.
40. Epelman S, Shrestha K, Troughton RW et al. Soluble angiotensin-converting enzyme 2 in human heart failure: Relation with myocardial function and clinical outcomes. J. Cardiac Fail. 2009; 15: 565-71.
41. Wang Y, Moreira Mda C, Heringer-Walther S et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J. Cardiac Fail. 2010; 16: 157-63.
42. Soro-Paavonen A, Gordin D, Forsblom C et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J. Hypertens. 2012; 30: 375-83.
43. Chong CP, Lim WK, Velkoska E et al. N-Terminal pro-brain natriuretic peptide and angiotension converting enzyme 2 levels and their association with post-operative cardiac complications after emergency orthopaedic Surgery. Am. J. Cardiol. 2012; 109: 1365-73.
44. Lehmann HI, Wolke C, Malenke W et al. Enzymatic activity of DPIV and renin-angiotensin system (RAS) proteases in patients with left ventricular dysfunction and primary prevention implantable cardioverter/defibrillator (ICD). Int. J. Cardiol. 2012; Epub 10 October 2012; doi:10.1016/j.ijcard.2012.09.083
45. Soler MJ, Riera M, Crespo M et al. Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: A longitudinal pilot study. Nephron. Clin. Pract. 2012; 121: c144-50.
46. Roberts MA, Velkoska E, Ierino FL, Burrell LM. Angiotensin converting enzyme 2 in patients with chronic kidney disease. Nephrol. Dial. Transplant. 2013; Epub 27 March 2013; doi:10.1093/ndt/gft038.
47. Smith AI, Warner FJ, Lew RA, Yarski M, McGrath B, Burrell LM. Quenched fluorescent peptide substrates as tools for the discovery of novel cardiovascular disease biomarkers. Adv. Exp. Med. Biol. 2009; 611: 419-22.
48. Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E. Chronic kidney disease. Cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp. Physiol. 2012; 97: 477-85.
49. Trask AJ, Groban L, Westwood BM et al. Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 fypertensive rats. Am. J. Hypertens. 2010; 23: 687-93.
50. Velkoska E, Dean RG, Griggs K, Burchill L, Burrell LM. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin. Sci. 2011; 120: 335-45.
51. Prieto MC, Gonzalez-Villalobos RA, Botros FT et al. Reciprocal changes in renal ACE/Ang II and ACE2/Ang 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am. J. Physiol. Renal Physiol. 2011; 300: F749-55.
52. Tikellis C, Bialkowski K, Pete J et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-25.
53. Ye M, Wysocki J, Gonzalez-Pacheco FR et al. Murine recombinant angiotensin-converting enzyme 2: Effect on angiotensin II dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-eonverting enzyme 2. Hypertension 2012; 60: 730-40.
54. Pedersen KB, Sriramula S, Chhabra KH, Xia H, Lazartigues E. Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. Am. J. Physiol. Regul. Intergr. Comp. Physiol. 2011; 301: R1293-9.
55. Wysocki J, Ye M, Soler MJ et al. ACE and ACE2 activity in diabetic mice. Diabetes 2006; 55: 2132-9.
56. Freeman M, Patel SK, Lancefield T et al. Angiotensin converting enzyme 2: A novel marker of coronary artery disease. Eur. Heart J. 2011; 31: 515. (Abstract).
57. Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: Its potential as a functional candidate for cardiovascular disease. Clin. Sci. 2013; 124: 65-76.
58. Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004; 2: 19.
59. Richards M, Troughton RW. NT-proBNP in heart failure. Therapy decisions and monitoring. Eur. J. Heart Fail. 2004; 6: 351-4.
60. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004; 351: 1296-305.
61. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin. Sci. (Lond) 2012; 123: 225-39.